Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation

NCT07456046 is registered in ClinicalTrials.gov with D3 Bio (Wuxi) Co., Ltd as lead sponsor.

NCT NCT07456046
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07456046 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-label, Dose-Escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of D3S-003 Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation
Lead sponsor
D3 Bio (Wuxi) Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
May 29, 2026
Completion date
January 11, 2028
Enrollment
42 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

kras p.g12d